Amyotrophic Lateral Sclerosis Market Research Report: By Type (Familial ALS), by Treatment (Medication, Physical Therapy, Speech Therapy), by Diagnosis (Laboratory Tests, Imaging Tests), End-User (Hospitals, Specialty Centers) – Global forecast till 2023

Market Scenario

Amyotrophic lateral sclerosis is a neurodegenerative disease. ALS affects the nerve cells in the brain and spinal cord that control the voluntary muscles. It is also known as the Lou Gehrig’s disease. Amyotrophic lateral sclerosis can be caused due to various factors such as genetics or environmental factors such as exposure to toxic or infectious agents, viruses, physical trauma, diet, and behavioral and occupational factors.

The global amyotrophic lateral sclerosis market is majorly driven by the growing prevalence of ALS, rising older population leading to rise in the patient population. Additionally, government funding, rising programs to create awareness, and market players offering advanced products are likely to drive the market.

According to the United Nations, in 2017 approximately over 962 million population were aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This is likely to propel the growth of the global amyotrophic lateral sclerosis market. Factors that are likely to hamper the growth of the market is the lack of awareness regarding the treatment.

Global amyotrophic lateral sclerosis market is expected to grow at a CAGR of 6% during the forecast period.

Figure: Global Amyotrophic Lateral Sclerosis Market, by Region, 2016 (%)
Intended Audience

- Pharmaceutical Manufacturers and Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

Research Methodology


Segments

The global amyotrophic lateral sclerosis market is segmented on the basis of type, treatment, diagnosis, and end-user.

On the basis of type, the market is segmented into Familial ALS and Sporadic ALS.

On the basis of diagnosis, the market is segmented into laboratory tests, imaging tests, and others. On the basis of diagnosis, laboratory tests are further sub-segmented into blood tests, urine tests, and thyroid functioning tests. On the basis of imaging test, it is further sub-divided into Electromyography (EMG), X-ray, and Nerve Conduction Study (NCS).

On the basis of treatment, the market is segmented into medication, physical therapy, speech therapy, nutritional support, and breathing support. On the basis of treatment, medication is further sub-segmented into Edaravone and Riluzole.

On the basis of end-user, the market is segmented into specialty centers, hospitals, and research centers.

Regional Analysis

The North American amyotrophic lateral sclerosis market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing prevalence of ALS affected population, along with the rising older population is likely to drive the market. Additionally, growing healthcare expenditure and rising demand for technologically advanced treatment and products along with the rising government support is likely to enhance the growth of the
Amyotrophic lateral sclerosis (ALS) market in North America. For instance, in 2015, a group of ALS organizations in the U.S., such as ALS Association, Les Turner ALS Foundation, and ALS Therapy Development Institute, introduced the Ice Bucket Challenge to raise further funds and spread awareness about ALS among the population.

Europe is the second largest market and holds a healthy share in the global amyotrophic lateral sclerosis market. The European market is expected to grow at a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and rising skilled medical professionals along with the growing need for better healthcare scenario. Furthermore, rising older population, along with growing inclination towards sedentary lifestyle is driving the growth of the amyotrophic lateral sclerosis market.

Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases and infections are the major drivers for the market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. The increasing awareness regarding the health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and change in the standard of living are driving the growth of the amyotrophic lateral sclerosis market in the Asia Pacific region.

The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the rise in healthcare development and rising demand for availability of specialty care centers.

**Key Players**

Some of the key players in the Amyotrophic Lateral Sclerosis market are GNT Pharma, Synthetic Biologics, Avicena Inc., Amkor Pharma, Mitsubishi Tanabe Pharma, Sanofi, and Biogen Inc., among others.
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Amyotrophic Lateral Sclerosis Market, by Type
6.1 Introduction
6.2 Familial ALS
6.2.1 Market Estimates & Forecast, 2017–2023
6.3 Sporadic ALS
6.3.1 Market Estimates & Forecast, 2017–2023

7. Global Amyotrophic Lateral Sclerosis Market, by Diagnosis
7.1 Introduction
7.2 Laboratory Tests
7.2.1 Blood Tests
7.2.2 Urine Tests
7.2.3 Thyroid Functioning Tests
7.2.4 Market Estimates & Forecast, 2017–2023
7.3 Imaging Tests
7.3.1 Electromyography (EMG)
7.3.2 X-rays
7.3.3 Nerve Conduction Study (NCS)
7.3.4 Market Estimates & Forecast, 2017–2023
7.4 Others
7.4.1 Market Estimates & Forecast, 2017–2023

8. Global Amyotrophic Lateral Sclerosis Market, by Treatment
8.1 Introduction
8.2 Medication
8.2.1 Riluzole (Rilutek)
8.2.2 Edaravone (Radicava)
8.2.1 Market Estimates & Forecast, 2017–2023
8.3 Physical Therapy
8.3.1 Market Estimates & Forecast, 2017–2023
8.4 Speech Therapy
8.4.1 Market Estimates & Forecast, 2017–2023
8.5 Nutritional Support
8.5.1 Market Estimates & Forecast, 2017–2023
8.6 Breathing Support
8.6.1 Market Estimates & Forecast, 2017–2023

9. Global Amyotrophic Lateral Sclerosis Market, by End-User
9.1 Introduction
9.2 Hospitals
9.2.1 Market Estimates & Forecast, 2017–2023
9.3 Specialty Centers
9.3.1 Market Estimates & Forecast, 2017–2023
9.4 Research Centers
9.4.1 Market Estimates & Forecast, 2017–2023

10 Global Amyotrophic Lateral Sclerosis Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
11 Company Landscape

11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

12 Company Profiles

12.1 GNT Pharma
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis

12.2 Synthetic Biologics
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis

12.3 Avicena Inc.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis

12.4 Amkor Pharma
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis

12.5 Mitsubishi Tanabe Pharma
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial Overview
12.5.4 Key Developments

12.6 Sanofi
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments

12.7 Biogen Inc.
LIST OF TABLES
Table 1 Amyotrophic Lateral Sclerosis Industry Synopsis, 2017–2023
Table 2 Global Amyotrophic Lateral Sclerosis Market Estimates & Forecast, 2017–2023, (USD Million)
Table 3 Global Amyotrophic Lateral Sclerosis Market, by Region, 2017–2023, (USD Million)
Table 5 Global Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 6 Global Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 7 Global Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 8 North America Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 9 North America Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 10 North America Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 11 U.S. Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 12 U.S. Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 13 U.S. Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 14 Canada Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 15 Canada Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 16 Canada Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 17 South America Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 18 South America Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 19 South America Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 20 Europe Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 21 Europe Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 22 Europe Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 23 Western Europe Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 24 Western Europe Amyotrophic Lateral Sclerosis Market, by Diagnosis, 2017–2023, (USD Million)
Table 25 Western Europe Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 26 Eastern Europe Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 27 Eastern Europe Amyotrophic Lateral Sclerosis Market, by diagnosis, 2017–2023, (USD Million)
Table 28 Eastern Europe Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 29 Asia Pacific Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 30 Asia Pacific Amyotrophic Lateral Sclerosis Market, by diagnosis, 2017–2023, (USD Million)
Table 31 Asia Pacific Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)
Table 32 Middle East & Africa Amyotrophic Lateral Sclerosis Market, by Treatment, 2017–2023, (USD Million)
Table 33 Middle East & Africa Amyotrophic Lateral Sclerosis Market, by diagnoses, 2017–2023, (USD Million)
Table 34 Middle East & Africa Amyotrophic Lateral Sclerosis Market, by End-User, 2017–2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Amyotrophic Lateral Sclerosis Market
Figure 3 Segmentation Market Dynamics for Amyotrophic Lateral Sclerosis Market
Figure 4 Global Amyotrophic Lateral Sclerosis Market Share, by Treatment 2016
Figure 5 Global Amyotrophic Lateral Sclerosis Market Share, by Diagnosis 2016
Figure 6 Global Amyotrophic Lateral Sclerosis Market Share, by End-User, 2016
Figure 7 Global Amyotrophic Lateral Sclerosis Market Share, by Region, 2016
Figure 8 North America Amyotrophic Lateral Sclerosis Market Share, by Country, 2016
Figure 9 Europe Amyotrophic Lateral Sclerosis Market Share, by Country, 2016
Figure 10 Asia Pacific Amyotrophic Lateral Sclerosis Market Share, by Country, 2016
Figure 11 Middle East & Africa Amyotrophic Lateral Sclerosis Market Share, by Country, 2016
Figure 12 Global Amyotrophic Lateral Sclerosis Market: Company Share Analysis, 2016 (%)
Figure 13 Biogen, Inc: Key Financials
Figure 14 Biogen, Inc: Segmental Revenue
Figure 16 Biogen, Inc: Geographical Revenue
Figure 17 GNT Pharma: Key Financials
Figure 18 GNT Pharma: Segmental Revenue
Figure 19 GNT Pharma: Geographical Revenue
Figure 20 Avicena Inc.: Key Financials
Figure 21 Avicena Inc.: Segmental Revenue
Figure 22 Avicena Inc. Geographical Revenue
Figure 23 Sanofi: Key Financials
Figure 24 Sanofi: Segmental Revenue
Figure 25 Sanofi: Geographical Revenue
Figure 26 Impax Laboratories: Key Financials
Figure 27 Impax Laboratories: Segmental Revenue
Figure 28 Impax Laboratories. Geographical Revenue
Figure 29 Ardelyx, Inc.: Key Financials
Figure 30 Ardelyx, Inc.: Segmental Revenue
Figure 31 Ardelyx, Inc.: Geographical Revenue
Figure 32 Mylan Pharmaceuticals Inc.: Key Financials
Figure 33 Mylan Pharmaceuticals Inc.: Segmental Revenue

Figure 34 Mylan Pharmaceuticals Inc.: Geographical Revenue